Celltrion Healthcare (Formerly Known As Celltrion)
1000 Marina Boulevard
Suite 200
Brisbane
California
94005
United States
Website: http://www.celltrionhealthcare.com/
Email: sshong@celltrion.com
About Celltrion Healthcare (Formerly Known As Celltrion)
Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.YEAR FOUNDED:
1999
LEADERSHIP:
CEO: Jung Jini
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW CELLTRION:
Tweets by Celltrion
101 articles about Celltrion Healthcare (Formerly Known As Celltrion)
-
Celltrion presents strategic vision and growth plan at the 42nd Annual J.P. Morgan Healthcare Conference
1/11/2024
Celltrion, Inc. announced the next phase of its strategic transformation from a developer of the world's first monoclonal antibody biosimilar to an innovative company focused on new drug development at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.
-
The regulator has approved the first-ever subcutaneous version of infliximab, an IgG1 monoclonal antibody, commonly sold by Johnson & Johnson under the brand name Remicade.
-
Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger
10/23/2023
Celltrion Group announced that the merger agreement between Celltrion, Inc. and Celltrion Healthcare Co., Ltd. was approved at the extraordinary general meeting of shareholders of the two companies held at Songdo Convensia and Sheraton Grand Incheon Hotel, respectively, on October 23, 2023.
-
Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease
10/23/2023
Celltrion USA announced that the U.S. Food and Drug Administration has approved ZYMFENTRA® for maintenance therapy in adults with moderately to severely active ulcerative colitis and Crohn’s disease following treatment with an infliximab product administered intravenously.
-
Celltrion USA Launches Yuflyma® (adalimumab-aaty), a Humira® (adalimumab) biosimilar, in the United States
7/3/2023
Celltrion USA announced the launch of Yuflyma®, a high-concentration and citrate-free formulation of Humira® biosimilar, providing an alternative option for patients.
-
AbbVie’s Humira will now face competition from new biosimilars, including Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.
-
Celltrion Healthcare Presents Efficacy and Safety Data From Global Phase III LIBERTY Trial, at the 18th ECCO Congress
3/3/2023
Celltrion Healthcare presented new data demonstrating the efficacy and safety of subcutaneous infliximab in patients with inflammatory bowel disease.
-
Celltrion Healthcare announces Canadian approval of Vegzelma (bevacizumab for injection) for the treatment of five types of cancer
1/19/2023
Vegzelma ® , a bevacizumab biosimilar of Avastin ® , is now approved by Health Canada Vegzelma ® offers Canadian patients living with one of five types of cancer a new treatment option Celltrion Healthcare Canada Limited is committed to providing a patient centric approach, to ensure access to innovative, high quality, and affordable biologics in Canada.
-
Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration
12/22/2022
Celltrion USA announced the submission of a Biologics License Application under the 351 pathway of the Public Health Service Act for lead product candidate, CT-P13 SC, which is the subcutaneous formulation of infliximab to the U.S. Food and Drug Administration.
-
The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more.
-
Celltrion USA Receives U.S. FDA Approval for its Oncology Biosimilar Vegzelma® (bevacizumab-adcd) for the Treatment of Six Types of Cancer
9/28/2022
Celltrion USA announced that the U.S. Food and Drug Administration has approved Vegzelma®, a biosimilar to Avastin®, for the treatment of six types of cancer.
-
Celltrion agreed Wednesday to jointly develop Abpro’s cancer molecule ABP-102 in a deal that could net as much as $1.75 billion. See inside for more cancer collaborations.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
-
Celltrion Submits Investigational New Drug (IND) Application to Initiate a Global Phase III Clinical Trial Evaluating an Inhaled COVID-19 Antibody Cocktail Therapy
2/7/2022
Celltrion Group announced it has submitted an Investigational New Drug application to conduct a global Phase III clinical trial evaluating the efficacy and safety of an inhaled COVID-19 antibody cocktail therapy for patients with mild-to-moderate symptoms of COVID-19; the trial is expected to enrol 2,200 patients globally.
-
Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant
1/3/2022
Celltrion Group announced results for its cocktail therapy candidates including neutralisation data against the Omicron variant.
-
Low-income countries still struggle to get first jabs into arms. Researchers and pharma companies continue to push for low-cost vaccines and drugs worldwide.
-
The Pfizer-BioNTech vaccine (now Comirnaty®) was fully approved by the U.S. Food and Drug Administration (FDA) on August 23 and boosters of this shot are now available to the most vulnerable Americans.
-
Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications
9/20/2021
180 Life Sciences Corp. announced that they have entered into a Memorandum of Understanding, with Celltrion Healthcare, a leading biopharmaceutical company, for the supply of anti-TNF biosimilar drug used in the ongoing development of anti-TNF products for new indications with significant unmet medical needs.
-
Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
9/18/2021
Celltrion Group announced that the Korean Ministry of Food and Drug Safety approved regdanvimab, a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19.